Evidence map›Paper›PMID 23851935›Full record

ReviewTransplantation2013

New concepts of immune modulation in xenotransplantation.

Vikas Satyananda, Hidetaka Hara, Mohamed B Ezzelarab, Carol Phelps, David Ayares, David K C Cooper

Abstract readEditorialReview
In one paragraph

Review in Transplantation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Cardiac Xenotransplantation: Challenges, Evolution, and Advances.JACC. Basic to translational science · 2022
    Review
  3. Article
  4. Article
  5. CRISPR/Cas Technology in Pig-to-Human Xenotransplantation Research.International journal of molecular sciences · 2021
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Respiratory nanoparticle-based vaccines and challenges associated with animal models and translation.Journal of controlled release : official journal of the Controlled Release Society · 2015
    Review
  15. Immunobiological barriers to xenotransplantation.International journal of surgery (London, England) · 2015
    Review
  16. Article
  17. Complement inhibition in a xenogeneic model of interactions between human whole blood and porcine endothelium.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2015
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Vikas Satyananda1 Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA. 2 Revivicor, Blacksburg, VA. 3 Address correspondence to: David K.C. Cooper, M.D., Ph.D., F.R.C.S., Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Biomedical Science Tower, W1543, 200 Lothrop Street, Pittsburgh, PA.
Hidetaka Hara
Mohamed B Ezzelarab
Carol Phelps
David Ayares
David K C Cooper
University of Pittsburgh Medical Center · US

Funding

University of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8M
Prolonging life-supported pig kidney and heart graft survival in baboons by suppressing inflammationU19AI090959 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MOHIUDDIN, MUHAMMAD M · 2010 to 2024
$26.3M
Therapeutic assessment of synthetic heparin sulfates in transplantation modelsP01HL107152 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI DESAI, UMESH RAMANLAL · 2011 to 2017
$15.8M
Thromboregulatory strategies to prolong xenograft survival.U01AI066331 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ROBSON, SIMON C. · 2005 to 2009
$4.1M
ENDOSCOPIC BIOPSY OF ISLET TRANSPLANTS IN THE GASTRIC SUBMUCOSAL SPACE IN PIGSR03AI096296 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HARA, HIDETAKA · 2011 to 2012
$152k
NCATS NIH HHS UL1 TR000005NHLBI NIH HHS P01 HL107152NHLBI NIH HHS P01 HL107152-02NIAID NIH HHS R03 AI096296NIAID NIH HHS U01 AI066331NIAID NIH HHS U19 AI090959PHS HHS R03A1096296-01PHS HHS U01A1066331PHS HHS U19A1090959-01
6 · The paper itself

Abstract

The shortage of human organs for transplantation has focused research on the possibility of transplanting pig organs into humans. Many factors contribute to the failure of a pig organ graft in a primate. A rapid innate immune response (natural anti-pig antibody, complement activation, and an innate cellular response; e.g., neutrophils, monocytes, macrophages, and natural killer cells) is followed by an adaptive immune response, although T-cell infiltration of the graft has rarely been reported. Other factors (e.g., coagulation dysregulation and inflammation) appear to play a significantly greater role than in allotransplantation. The immune responses to a pig xenograft cannot therefore be controlled simply by suppression of T-cell activity. Before xenotransplantation can be introduced successfully into the clinic, the problems of the innate, coagulopathic, and inflammatory responses will have to be overcome, most likely by the transplantation of organs from genetically engineered pigs. Many of the genetic manipulations aimed at protecting against these responses also reduce the adaptive response. The T-cell and elicited antibody responses can be prevented by the biological and/or pharmacologic agents currently available, in particular, by costimulation blockade-based regimens. The exogenous immunosuppressive regimen may be significantly reduced by the presence of a graft from a pig transgenic for a mutant (human) class II transactivator gene, resulting in down-regulation of swine leukocyte antigen class II expression, or from a pig with "local" vascular endothelial cell expression of an immunosuppressive gene (e.g., CTLA4-Ig). The immunomodulatory efficacy of regulatory T cells or mesenchymal stromal cells has been demonstrated in vitro but not yet in vivo.

Indexed as

Graft SurvivalImmunosuppression TherapyTransplantation ToleranceAdaptive ImmunityAnimalsAnimals, Genetically ModifiedGenetic TherapyGraft RejectionHumansImmunity, InnateImmunosuppressive AgentsPrimatesSwineTissue DonorsT-LymphocytesTransplantation, HeterologousImmunosuppressive Agents

Identifiers

PMID23851935
PMCPMC4137477
OpenAlexW2036688433

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.